Insider Selling: Mesa Laboratories, Inc. (MLAB) Director Sells 3,000 Shares of Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John Bradley Schmieder sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the director now directly owns 77,869 shares in the company, valued at $10,299,732.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Mesa Laboratories, Inc. (NASDAQ MLAB) traded down $0.72 on Thursday, reaching $132.56. The company’s stock had a trading volume of 33,795 shares, compared to its average volume of 19,244. Mesa Laboratories, Inc. has a 12-month low of $117.58 and a 12-month high of $169.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.97 and a current ratio of 2.86. The firm has a market capitalization of $548.63, a price-to-earnings ratio of -132.70 and a beta of 0.52.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a negative net margin of 3.82% and a positive return on equity of 9.04%. The business had revenue of $22.95 million during the quarter, compared to analyst estimates of $25.50 million. equities research analysts expect that Mesa Laboratories, Inc. will post 2.42 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Wednesday, February 28th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Tuesday, February 27th. Mesa Laboratories’s payout ratio is -64.00%.

Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Mesa Laboratories by 35.0% during the fourth quarter. Wells Fargo & Company MN now owns 5,902 shares of the medical instruments supplier’s stock worth $734,000 after purchasing an additional 1,531 shares during the period. Keybank National Association OH raised its position in shares of Mesa Laboratories by 13.2% during the fourth quarter. Keybank National Association OH now owns 3,850 shares of the medical instruments supplier’s stock worth $479,000 after purchasing an additional 450 shares during the period. Candriam Luxembourg S.C.A. raised its position in shares of Mesa Laboratories by 20.0% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 7,200 shares of the medical instruments supplier’s stock worth $895,000 after purchasing an additional 1,200 shares during the period. Comerica Bank raised its position in shares of Mesa Laboratories by 86.2% during the fourth quarter. Comerica Bank now owns 6,481 shares of the medical instruments supplier’s stock worth $849,000 after purchasing an additional 3,000 shares during the period. Finally, Victory Capital Management Inc. raised its position in shares of Mesa Laboratories by 17.2% during the fourth quarter. Victory Capital Management Inc. now owns 172,774 shares of the medical instruments supplier’s stock worth $21,476,000 after purchasing an additional 25,306 shares during the period. 71.29% of the stock is currently owned by institutional investors.

Several equities analysts have issued reports on MLAB shares. TheStreet raised Mesa Laboratories from a “c+” rating to a “b” rating in a research note on Monday, November 6th. Zacks Investment Research lowered Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research note on Friday, November 10th. Finally, BidaskClub lowered Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th.

TRADEMARK VIOLATION WARNING: “Insider Selling: Mesa Laboratories, Inc. (MLAB) Director Sells 3,000 Shares of Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/08/insider-selling-mesa-laboratories-inc-mlab-director-sells-3000-shares-of-stock.html.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply